beam therapeutics is developing precision genetic medicines for serious diseases. co-founded by scientific pioneers known for advancing crispr gene editing, we’re the first company to pursue development of new therapies using crispr base editing technology. we aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. who we are beam is creating precision genetic medicines through base editing why we do it our dream is to provide life-long cures for patients suffering from serious diseases who we are and how we work together the beam team: a community of fearless innovators rigorous and honest in our research listening with open minds committed to each other
Company profile
Ticker
BEAM
Exchange
Website
CEO
John M. Evans
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Beam Therapeutics Securities Corporation • Guide Therapeutics, LLC ...
BEAM stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
19 Apr 24
DEFA14A
Additional proxy soliciting materials
19 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
S-3ASR
Automatic shelf registration
27 Feb 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
27 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
Latest ownership filings
4
Terry-Ann Burrell
29 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Amy Simon
3 Apr 24
4
Christine Bellon
3 Apr 24
4
Terry-Ann Burrell
3 Apr 24
4
John M. Evans
3 Apr 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 294.30 mm | 294.30 mm | 294.30 mm | 294.30 mm | 294.30 mm | 294.30 mm |
Cash burn (monthly) | 50.10 mm | (no burn) | 34.71 mm | 15.14 mm | 33.25 mm | 11.59 mm |
Cash used (since last report) | 79.44 mm | n/a | 55.03 mm | 24.00 mm | 52.71 mm | 18.38 mm |
Cash remaining | 214.86 mm | n/a | 239.27 mm | 270.30 mm | 241.59 mm | 275.92 mm |
Runway (months of cash) | 4.3 | n/a | 6.9 | 17.9 | 7.3 | 23.8 |
Institutional ownership, Q4 2023
23.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 20 |
Opened positions | 3 |
Closed positions | 176 |
Increased positions | 5 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 262.43 bn |
Total shares | 19.57 mm |
Total puts | 100.00 |
Total calls | 0.00 |
Total put/call ratio | Infinity |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 9.39 mm | $255.70 bn |
ARCH Venture Fund IX | 5.84 mm | $0.00 |
Farallon Capital Partners | 3.95 mm | $98.86 mm |
Mirae Asset Global Investments | 166.38 k | $4.53 bn |
International Assets Investment Management | 68.05 k | $2.50 mm |
DekaBank Deutsche Girozentrale | 50.00 k | $1.47 mm |
Harbor Capital Advisors | 34.92 k | $950.47 mm |
Arizona State Retirement System | 18.82 k | $512.25 mm |
SG Americas Securities | 14.84 k | $404.00 k |
Green Alpha Advisors | 13.91 k | $378.60 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
26 Apr 24 | Terry-Ann Burrell | Common Stock | Grant | Acquire A | No | No | 0 | 12,500 | 0.00 | 82,637 |
26 Apr 24 | Terry-Ann Burrell | Stock Option Common Stock | Grant | Acquire A | No | No | 30.87 | 25,000 | 771.75 k | 25,000 |
3 Apr 24 | Giuseppe Ciaramella | Stock Option Common Stock | Grant | Acquire A | No | No | 4.22 | 12,979 | 54.77 k | 12,979 |
3 Apr 24 | Giuseppe Ciaramella | Stock Option Common Stock | Grant | Acquire A | No | No | 0.67 | 27,318 | 18.30 k | 27,318 |
3 Apr 24 | John M. Evans | Stock Option Common Stock | Grant | Acquire A | No | No | 4.22 | 53,965 | 227.73 k | 53,965 |
3 Apr 24 | John M. Evans | Stock Option Common Stock | Grant | Acquire A | No | No | 0.67 | 99,336 | 66.56 k | 99,336 |
1 Apr 24 | Giuseppe Ciaramella | Common Stock | Sell | Dispose S | No | Yes | 32.12 | 4,534 | 145.63 k | 169,616 |
1 Apr 24 | John M. Evans | Common Stock | Sell | Dispose S | No | Yes | 32.13 | 18,102 | 581.62 k | 1,058,343 |
1 Apr 24 | Terry-Ann Burrell | Common Stock | Sell | Dispose S | No | Yes | 32.12 | 5,446 | 174.93 k | 70,137 |
1 Apr 24 | Christine Bellon | Common Stock | Sell | Dispose S | No | Yes | 32.12 | 3,401 | 109.24 k | 104,594 |
News
Bitcoin, Ethereum, Dogecoin Spike On Good Macro News: 'So Far, So Good,' Says Bullish Trader
15 May 24
Beam Therapeutics Presents Data Highlighting Robust Manufacturing Process For BEAM-101 At EHA 2024 Hybrid Congress June 13-16, 2024
14 May 24
Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $33
8 May 24
Expert Ratings For Beam Therapeutics
23 Apr 24
Bitcoin Surpasses $66,000; Akash Network, Core Among Top Gainers
23 Apr 24
Press releases
Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
14 May 24
Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
8 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7 May 24
2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers
22 Mar 24
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
28 Feb 24